Torkinib (PP242)

Catalog No.S2218

Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Torkinib (PP242) Chemical Structure

Torkinib (PP242) Chemical Structure
Molecular Weight: 308.34

Validation & Quality Control

7 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Torkinib (PP242) is available in the following compound libraries:

mTOR Inhibitors with Unique Features

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively.
Targets mTOR [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)

 View  More

IC50 8 nM 0.10 μM 0.41 μM 0.41 μM
In vitro PP242 exhibits potent selectivity for mTOR over other PI3K family kinases such as p110α, p110β, p110γ, p110δ, and DNA-PK with IC50 of 1.96 μM, 2.2 μM, 1.27 μM, 0.102 μM, and 0.408 μM, respectively. PP242 displays some inhibitory activity against Ret, PKCα, PKCβ, and JAK2, while exhibits remarkable selectivity against 215 other protein kinases. Unlike rapamycin, PP242 inhibits both mTORC1 and mTORC2. In BT549 cells, PP242 treatment (0.04-10 μM) inhibits the phosphorylation of Akt, the mTOR substrate p70S6K, and its downstream target S6 in a dose-dependent manner. [1] PP242 potently inhibits PKCα with IC50 of 49 nM. Low concentrations of PP242 inhibit the phosphorylation of Akt S473 and higher concentrations partially inhibit Akt T308-P in addition to S473-P. As PP242 is a more effective mTORC1 inhibitor than rapamycin, PP242 inhibits the proliferation of primary MEFs, and the phosphorylation of 4EBP1 at T36/45 and S65, more potently than rapamycin. PP242 but not rapamycin potently inhibits cap-dependent translation, by causing a higher level of binding between 4EBP1 and eIF4E than rapamycin. [2] PP242 potently inhibits the proliferation of p190-transformed murine BM, SUP-B15, and K562 cells with GI50 of 12 nM, 90 nM, and 85 nM, respectively. PP242 also inhibits the growth of solid tumor cell lines such as SKOV3, PC3, 786-O, and U87 with GI50 of 0.49 μM, 0.19 μM, 2.13 μM, and 1.57 μM, respectively. [3] PP242 is also more effective than rapamycin in achieving cytoreduction and apoptosis in multiple myeloma (MM) cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-p21Ml;kSpVv[3Srb36gRZN{[Xl?MX61NE0yOjVyIH7NMl;YNlQhcA>?NG[4fmhFVVORNYXJclZscW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKFN4IHvpcoF{\SBqdHHy[4V1KG:oIH3UU3JEOSliYX7kJIl1eyCmb4fud5Rz\WGvIIThdodmfCCyaH;zdIhwNVN4wrC=MmPuNlYyPzdyNUG=
U87vIII MnqzSpVv[3Srb36gRZN{[Xl?NXfGNHZ2OC5yND2yMlUh|ryPNWXnZmNpOjRiaB?=NX\3c5ZKcW6qaXLpeJMhdVSRUlOxJIFv\CCvVF;SR|Ih[WO2aY\peIlme8LiMX6yOlE{PDZzNx?=
U87vIII NF3XPVhHfW6ldHnvckBCe3OjeR?=NVy1N|dZOi53L{Wg{txONHSxNGQyOiCqNVXMXphLcW6qaXLpeJMh\2GyIHPsc5NqdmdiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?NGGwNZozPjF|NE[xOy=>
PC12 NELjclVHfW6ldHnvckBCe3OjeR?=NF20ZY41OMLibl2=NYftbHFWcW6mdXPld{BtgXOxc3;tZYwh[mmxZ3Xu[ZNqeyCjbnSgZYxt\X[rYYTl[EDPuS2VWV6gZYNkfW23bHH0bY9vyqB?M{G0WFI3ODBzNkG0
3T3-L1NFPFV3VHfW6ldHnvckBCe3OjeR?=MmXBNVUh|ryPNFLUfJk1KGh?MnfKd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIITo[UBG\3JzIIDyc5RmcW8EoB?=NYXPc3lHOjV6MUS2OlI>
Rh30NHvO[VdHfW6ldHnvckBCe3OjeR?=MUmxJO69VQ>?MmfCNkBpNITRPHVqdmirYnn0d{Bjd3SqIH3UU3JEOS2vZXTpZZRm\CCyaH;zdIhwenmuYYTpc44hd2ZiU{\LNUBidmRibWTPVmMzNW2nZHnheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCDa4S=NEPsdoszPTd4Mk[xPS=>
HT29NXTIeY84TnWwY4Tpc44hSXO|YYm=NF3telAyKM7:TR?=NVzvRVhWOiCqM4j1UolvcGmkaYTzJIJwfGhibWTPVmMyNW2nZHnheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCVNluxJIFv\CCvVF;SR|IudWWmaXH0[YQheGixc4Doc5J6dGG2aX;uJI9nKEGtdB?=M{i4c|I2PzZ{NkG5
Rh30NX;qe29LTnWwY4Tpc44hSXO|YYm=NESzXHcyKM7:TR?=MkiyNkBpMlixd5VxeHKnc4Pld{B1cGViYnHzZYwhd3JiSVfGMVEue3SrbYXsZZRm\CClZXzsJIFlcGW|aX;uNGW5[mozPTd4Mk[xPS=>
HT29Mm\WSpVv[3Srb36gRZN{[Xl?NF\qeo8yKM7:TR?=NELjOZgzKGh?MnX1d5VxeHKnc4Pld{B1cGViYnHzZYwhd3JiSVfGMVEue3SrbYXsZZRm\CClZXzsJIFlcGW|aX;uM1fOOFI2PzZ{NkG5
U87NGfN[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTLdJRsOjVibl2=MXqyOEBpMojxbY5kemWjc3XzJGRWW1BzMDDrco9kc2WmLXTve44hcW6mdXPl[EBk\WyuIHnubIljcXSrb36=NHTiUIwzPTV4OE[2OS=>
AGSM1TpZWNmdGxiVnnhZoltcXS7IFHzd4F6M3H1OVAuOTByMDDuUS=>MXWyOE81QCCqMn;jSG1UVw>?M4TuOIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NHuyOZQzPTB|NUm2NS=>
MKN45MlLhR4VtdCCYaXHibYxqfHliQYPzZZk>NHfzdWcxNTFyMECgcm0>MY[yOE81QCCqMX3EUXNQMVTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVzM{TZXlI2ODN3OU[x
MKN28M2W4dWNmdGxiVnnhZoltcXS7IFHzd4F6MnLSNE0yODByIH7NNIHFV4MzPC92ODDoMnrySG1UVw>?MVPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVzNUjQeWNHOjVyM{W5OlE>
KATO3NITK[2hE\WyuIG\pZYJqdGm2eTDBd5NigQ>?Ml7hNE0yODByIH7NNHjBXFkzPC92ODDoNWjEOoZWTE2VTx?=MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVzMoH5NlUxOzV7NkG=
SGC7901MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MVSwMVExODBibl2=NH6yc|AzPC92ODDoMmXCSG1UVw>?MkXh[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?MXWyOVA{PTl4MR?=
N87MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MXewMVExODBibl2=Mk\RNlQwPDhiaB?=MoXUSG1UVw>?NUC3ZoZG\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=Mlu4NlUxOzV7NkG=
HMECMkfzR4VtdCCYaXHibYxqfHliQYPzZZk>NWLCSWRzOC1zMECwJI5ONGr6fIozPC92ODDoNUX2So5oTE2VTx?=M2XN[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?NVPTTldCOjVyM{W5OlE>
HUVECMknqR4VtdCCYaXHibYxqfHliQYPzZZk>M3L1Z|AuOTByMDDuUS=>MXGyOE81QCCqNES3WlBFVVORMV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6geIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVzNXn4cppzOjVyM{W5OlE>
MG63NH:5NItHfW6ldHnvckBCe3OjeR?=NXfMPJRRPTBvMUCwNEBvVQ>?MVmwMlUhcA>?MlW5[I9{\SCmZYDlcoRmdnSueTCoOVDjiJNzMECwJI5OMSCrbnjpZol1eyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0NXvCOYtGOjR6NECxN|Q>
U2OS NIH2PFNHfW6ldHnvckBCe3OjeR?=M{DDPFUxNTFyMECgcm0>NWPxO5RmOC53IHi=MVTkc5NmKGSncHXu[IVvfGy7IDi1NQKBmzFyMECgcm0qKGmwaHnibZR{KHCqb4PwbI9zgWyjdHnvckBw\iCDa4S=NHTZ[YczPDh2MEGzOC=>
Saos-2 MXzGeY5kfGmxbjDBd5NigQ>?M1vlT|UxNTFyMECgcm0>MVOwMlUhcA>?MlTP[I9{\SCmZYDlcoRmdnSueTCoOVDjiJNzMECwJI5OMSCrbnjpZol1eyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0MlThNlQ5PDBzM{S=
Saos-2NGnYOYJHfW6ldHnvckBCe3OjeR?=Mmq3NVAxKG6PNEXXNo0xNjViaB?=MVLwdoV3\W62czDvd5Rmd3OjcnPvcYEh[2WubDDtbYdz[XSrb36=NH21O3QzPDh2MEGzOC=>
MG63M3\tSmFxd3C2b4Ppd{BCe3OjeR?=MmXJNVAxKG6PMmH6N|YhcA>?M2rXTpBzd22xdHXzJIFxd3C2b4Ppdy=>MUGyOFg1ODF|NB?=
U2OS MliyRZBweHSxc3nzJGF{e2G7M1PnR|ExOCCwTR?=NFXtUXI{PiCqM13vOZBzd22xdHXzJIFxd3C2b4Ppdy=>MYGyOFg1ODF|NB?=
Saos-2 NHjYR|RCeG:ydH;zbZMhSXO|YYm=NVT4cYx2OTByIH7NNF3IWnY{PiCqNXLLRZczeHKxbX;0[ZMh[XCxcITvd4l{MXmyOFg1ODF|NB?=
HT1376NIm1[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXaSoR2UUN3ME2xMlg5KMLzIEGuNUDPxE1?MUWyOFA2PDh5MR?=
T24MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTFwM{egxtEhOC52IN88US=>M16xT|I1ODV2OEex
UM-UC-3MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXGwPHBIUUN3ME2wMlY{KMLzMD6xJO69VQ>?M3nkOFI1ODV2OEex
DLD-1MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=>M176ZlAuOTByMDDuUS=>NWG1OWxpOjRiaB?=NWPRWlhIcW6qaXLpeJMhfGinIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?MorYNlM6QTFzN{m=
Caco2MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NVHBUZFiOC1zMECwJI5OMnTDNlQhcA>?NWK1OG5RcW6qaXLpeJMhfGinIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?MXKyN|k6OTF5OR?=
HT29MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NFvMRXYxNTFyMECgcm0>NUTJSGkyOjRiaB?=MlvFbY5pcWKrdIOgeIhmKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>M2XoNlI{QTlzMUe5
H116M2DUN2NmdGxiVnnhZoltcXS7IFHzd4F6Ml3kNE0yODByIH7NMYmyOEBpM3W1eolvcGmkaYTzJJRp\SCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NG[3XWczOzl7MUG3PS=>
Hct-8NIDBfnBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NGLaV48xNTFyMECgcm0>M1vTNVI1KGh?NFe0[XBqdmirYnn0d{B1cGViZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzM2TmU|I{QTlzMUe5
Colo320NFHmVlhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?MWWwMVExODBibl2=NX3NRWlUOjRiaB?=NXW4O|ducW6qaXLpeJMhfGinIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?NGf6cW8zOzl7MUG3PS=>
Sw948MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NILJbXYxNTFyMECgcm0>NXzsZm1{OjRiaB?=M4LUfolvcGmkaYTzJJRp\SCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NGe5XGszOzl7MUG3PS=>
Colo205M1KyVWNmdGxiVnnhZoltcXS7IFHzd4F6MYWwMVExODBibl2=MVuyOEBpNGj5RodqdmirYnn0d{B1cGViZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzMYWyN|k6OTF5OR?=
Colo320M2T5[WZ2dmO2aX;uJGF{e2G7MX2xJO69VQ>?NXnvd|RsOC1{NDDoMlvjZYJwdGm|aHXzJJRp\SCVNmOyN|UwOjN4wrDieZQheGG{dHnhcIx6KHKnZIXj[ZMhfGinIETFMWJROVR|Nj:0OS=>NHrvXJczOzl7MUG3PS=>
HT29MU\GeY5kfGmxbjDBd5NigQ>?MVuxJO69VQ>?MnLwNE0zPCCqMlzVZYJwdGm|aHXzJJRp\SCVNmOyN|UwOjN4wrDieZQheGG{dHnhcIx6KHKnZIXj[ZMhfGinIETFMWJROVR|Nj:0OS=>MlPrNlM6QTFzN{m=
Sw948NInoUW1HfW6ldHnvckBCe3OjeR?=MkTTNUDPxE1?MYKwMVI1KGh?MXPhZo9tcXOqZYOgeIhmKFN4U{KzOU8zOzcEoHL1eEBx[XK2aXHscJkhemWmdXPld{B1cGViNFWtRnAyXDN4L{S1NFvkNYUzOzl7MUG3PS=>
DLD-1NYrSZ5BNTnWwY4Tpc44hSXO|YYm=M4DxelEh|ryPMU[wMVI1KGh?NX\mfW9N[WKxbHnzbIV{KHSqZTDTOnMzOzVxMkO2xsBjfXRicHHyeIlidGy7IILl[JVk\XNidHjlJFRGNUKSMWSzOk81PQ>?NEHGdlgzOzl7MUG3PS=>
SW620NYrVeGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTdwODFOwG0>Mn23NlM2PDJzN{i=
SW480M1ize2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFPmVJlKSzVyPUSuOkDPxE1?NIC1dZczOzV2MkG3PC=>
SK-CO-1NXPWXZQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfSNmduUUN3ME20JO69VQ>?NFnCVIkzOzV2MkG3PC=>
LS-513NGLuXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFSxcYFKSzVyPUOuPUDPxE1?MonSNlM2PDJzN{i=
SW1116NWj0fXJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoT0TWM2OD1yLki0JO69VQ>?NILFcJUzOzV2MkG3PC=>
LS-174TMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3rSVRQUUN3ME2wMlg1KM7:TR?=MV:yN|U1OjF5OB?=
HCT 116NHHMcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2P4XmlEPTB;MD60NUDPxE1?Mn3zNlM2PDJzN{i=
HCT 15MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrsTnZSUUN3ME2wMlMh|ryPNVTBbnhjOjN3NEKxO|g>
COLO 205NWPre2F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HkT2lEPTB;MD6yOEDPxE1?Mk\6NlM2PDJzN{i=
HT-29MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXaTWM2OD1yLkKzJO69VQ>?NWDPRolHOjN3NEKxO|g>
COLO 201M3X2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWn1TVlPUUN3ME2wMlI{KM7:TR?=M{nhTVI{PTR{MUe4
Caco-2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1mwOGlEPTB;MD6yNkDPxE1?NVjhZZEyOjN3NEKxO|g>
SW48M3jNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTBwMEmg{txOMnmwNlM2PDJzN{i=
DND-1NYG1dVdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLONolWOC5{NT:wMlUwOSEQvF2=M3XzZ2ROW09?MnHhbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=>MYSyN|Q5Ojd2OB?=
TMD8M3XEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\aS|AvOjVxMD61M|Eh|ryPM{HY[2ROW09?MofHbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=>NW\YblllOjN2OEK3OFg>
JurkatM1nyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;xRoUxNjJ3L{CuOU8yKM7:TR?=NF3iOotFVVORMonYbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=>NFjyb3UzOzR6Mke0PC=>
KOPT-K1MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXSwMlI2NzBwNT:xJO69VQ>?M1P2SmROW09?M2naXolvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>MVGyN|Q5Ojd2OB?=
TMD7M3vDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnj[FUxNjJ3L{CuOU8yKM7:TR?=MX;EUXNQMX7pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5MVyyN|Q5Ojd2OB?=
THP-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUWwMlI2NzBwNT:xJO69VQ>?NXrjSG5tTE2VTx?=MofWbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=>MnnPNlM1QDJ5NEi=
786-ONYL0[4FiTnWwY4Tpc44hSXO|YYm=NX3qSpk2OC5zL{CuOUDPxE1?M1rEVFI1KGh?M{\Rd2ROW09?NFfkcIRqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCvUl7BJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7MXGyN|E1PzJ3MR?=
786-ONIDjNnJHfW6ldHnvckBCe3OjeR?=MnHxNE0xNjVizszNMX2yOEBpNEnQXlFFVVORMVny[ZN2dHS|IHnuJIEh\G:|ZTDk[ZBmdmSnboSgbY5kemWjc3WgbY4hTS2lYXTo[ZJqdiCycn;0[YlvKGW6cILld5Nqd28EoB?=Mo\INlMyPDd{NUG=
OCI-AML3NYeyV2tCSXCxcITvd4l{KEG|c3H5M17lUlIvPSEQvF2=NXHucYpnPzJiaB?=MWLpcoR2[2W|IHHwc5B1d3Orcx?=M3z4RlIzQDJ4NU[1
JurkatNVnF[Wd[TnWwY4Tpc44hSXO|YYm=NXz5[mFkOTByL{KwNE81ODBibl2=NVn4NYRJOThiaB?=MYLpcohq[mm2czDtWG9TSzFvZHXw[Y5l\W62IGO2JHMzOzVxMkO2JJBpd3OyaH;yfYxifGmxbh?=MYKyNlU3PjZyNB?=
p210 BCR-AblM3jPVmZ2dmO2aX;uJGF{e2G7M33TZ|ExOC9{MECvOFAxKG6PNFfQUZgyQCCqNXT5SZBkcW6qaXLpeJMhdVSRUlOxMYRmeGWwZHXueEBUPiCVMkO1M|I{PiCyaH;zdIhwenmuYYTpc44>MXqyNlU3PjZyNB?=
JurkatM3fPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjTOFAxdk1?NIOxU4IzPC92ODDoNIfMZml{gW6ncnfpfoUhf2m2aDCxO{1CSUdidH:gd5VxeHKnc4OgZ4VtdCCycn;sbYZmemG2aX;uNVH6Zok1OjJ3Nk[2NFQ>
p210 BCR-AblMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG5NGk1ODCwTR?=MmLlNlQwPDhiaB?=MkjHd5lv\XKpaYrlJJdqfGhiMUetRWFIKHSxIIP1dJBz\XO|IHPlcIwheHKxbHnm[ZJifGmxbh?=MmTINlI2PjZ4MES=
8226M{LsUGZ2dmO2aX;uJGF{e2G7NFX0[3EyODBvMUCwNEBvVQ>?NGrzWpM{OCCvaX6=MYnEUXNQMX\hZ5RqfmG2ZYOgSXJMyqB?NV\xcZJ3OjJ3NU[0NFk>
MM1.S M{PGZWZ2dmO2aX;uJGF{e2G7M37xWVExOC1zMECwJI5ONGnRbWM{OCCvaX6=M{jxO2ROW09?NFK0OWJi[3SrdnH0[ZMhTVKNwrC=M{\MT|IzPTV4NEC5
8226NWP1ZmwxTnWwY4Tpc44hSXO|YYm=MXSwMlUh|ryPNEC5elQ{OCCvaX6=NYi4NlZuTE2VTx?=Mn\xbY5lfWOnczDhZ5RqfmG2aX;uJI9nKFKDRjDhcoQheGixc4Doc5J6dGG2aX;uJI9nKE2HSx?=MlTWNlI2PTZ2MEm=
MM1.S NUjq[o5KTnWwY4Tpc44hSXO|YYm=NU\NdoNYOC53IN88US=>NYn1NVhvOzBibXnuNICzSIFFVVORNXqyb4t1cW6mdXPld{Bi[3SrdnH0bY9vKG:oIGLBSkBidmRicHjvd5Bpd3K7bHH0bY9vKG:oIF3FTy=>MlHzNlI2PTZ2MEm=
MCF-7NXvlWYlOTnWwY4Tpc44hSXO|YYm=M{jPb|UxNzJyMD:1NFAhdk1?MXSzNEBucW5?M4LVS4Rwe2VvZHXw[Y5l\W62bImgLFUx6oDVNUCwxsBvVSlic4XwdJJme3OnczDwbI9{eGixconsZZRqd25ib3[gRYt1Mn\UNlI1PzZ6NUK=
T47DNITUV5dHfW6ldHnvckBCe3OjeR?=NIDwPZQ2OC9{MECvOVAxKG6PNXrmd40xOzBibXnuM1u3eoRwe2VvZHXw[Y5l\W62bImgLFUx6oDVNUCwxsBvVSlic4XwdJJme3OnczDwbI9{eGixconsZZRqd25ib3[gRYt1NULPWZdOOjJ2N{[4OVI>
MDA-MB-231NYjyVYtDTnWwY4Tpc44hSXO|YYm=NFXi[lI2OC9{MECvOVAxKG6PMknUN|AhdWmwMXPkc5NmNWSncHXu[IVvfGy7IDi1NQKBmzVyMNMgcm0qKHO3cIDy[ZN{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=>MVKyNlQ4Pjh3Mh?=
Bcap-37MojmSpVv[3Srb36gRZN{[Xl?MontOVAwOjByL{WwNEBvVQ>?MmLtN|AhdWmwMWLkc5NmNWSncHXu[IVvfGy7IDi1NQKBmzVyMNMgcm0qKHO3cIDy[ZN{\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=>M1\KNlIzPDd4OEWy
MCF-7Ml\lRZBweHSxc3nzJGF{e2G7M4DYdFIxOMLibl2=MlfQN|YhcA>?M4DPZ2ROW09?NEPHWHpqdmS3Y3XzJIFxd3C2b4Ppdy=>MUSyNlQ4Pjh3Mh?=
MDA-MB-231NHfUeINCeG:ydH;zbZMhSXO|YYm=M37HVVIxOMLibl2=MX2zOkBpMWDEUXNQM3PX[olv\HWlZYOgZZBweHSxc3nzMWOyNlQ4Pjh3Mh?=
Bcap-37NHfFR3FCeG:ydH;zbZMhSXO|YYm=M4nrUVIxOMLibl2=NYfGNHFyOzZiaB?=Ml\DSG1UVw>?MX\pcoR2[2W|IHHwc5B1d3Orcx?=NUXDN|A6OjJ2N{[4OVI>
LS174TNU\0N3ZNTnWwY4Tpc44hSXO|YYm=M4S2NVExNzFyMD:xNFAxKG6PMYS2JIg>M1zS[mROW09?MUHpcohq[mm2czDtWG9TSzFiYXP0bZZqfHliYomgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIGO2JJJq[m:|b33hcEBxem:2ZXnuM3\JSVIzPDBzMkm0
DLD-1 NV[2VZU6TnWwY4Tpc44hSXO|YYm=M1Sy[lExNzFyMD:xNFAxKG6PNVG5[|B6PiCqMXPEUXNQMkTjbY5pcWKrdIOgcXRQWkNzIHHjeIl3cXS7IHL5JJRp\SCmZYDoc5NxcG:{eXzheIlwdiCxZjDTOkBzcWKxc3;tZYwheHKxdHXpci=>M3PUbVIzPDBzMkm0
SW480NIPY[FZHfW6ldHnvckBCe3OjeR?=NH;aSZMyOC9zMECvNVAxOCCwTR?=M2nzTlYhcA>?MmfUSG1UVw>?M3\CcolvcGmkaYTzJI1VV1KFMTDhZ5Rqfmm2eTDifUB1cGViZHXwbI9{eGixconsZZRqd25ib3[gV|Yhemmkb4PvcYFtKHC{b4TlbY4>NEjRV|gzOjRyMUK5OC=>
SW-48M4f0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTBwMTFOwG0>MmqxNlIzPzB{NUe=
HCT-15MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWWzd|kzUUN3ME2wMlMh|ryPNYTYUFVCOjJ{N{CyOVc>
HCT 116MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTBwNjFOwG0>MXGyNlI4ODJ3Nx?=
SW620-RMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFe4NIxKSzVyPUGuN{DPxE1?MlvFNlIzPzB{NUe=
SK-CO-1NVnNWpZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4qzSmlEPTB;Mj6xJO69VQ>?MWCyNlI4ODJ3Nx?=
SW620MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTFzIN88US=>NWXNepdvOjJ{N{CyOVc>
BaF3NV74RnpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXQ[WtIUTVyPUGuOFQ6KM7:TR?=NH\wWVgzOjJ{M{[0OS=>
NIH 3T3NFLHZ|lHfW6ldHnvckBCe3OjeR?=M4DnN|Ih|ryPNV7XfnMxOThiaB?=M4HTWolvcGmkaYTzJI1VV1KFMjDwbI9{eGixconsZZRqd25ib3[gRYt1KG:wIGPldlQ4OyCjbnSgcXRQWkNzIIDoc5NxcG:{eXzheIlwdiCxZjC0SU1DWDFib36gWIhzOzdxNE[=NVLWVZpiOjF6N{[xN|A>
HCT15NIT6VpRHfW6ldHnvckBCe3OjeR?=M{nmb|AvPS9{IN88US=>NYnFRoFPPCCqMWrwdoV3\W62czDTOmsyKHCqb4PwbI9zgWyjdHnvckBw\iC{aXLvd49u[WxicILveIVqdiCVNjDheEBU\XJ{NECvNlQ1KGGwZDDtWG9TSzJicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O|M>NFzWfmYzOTh5NkGzNC=>
SW620 M{K5PGZ2dmO2aX;uJGF{e2G7MoDhNE42NzJizszNNHn0WG01KGh?M4frOoJtd2OtczDhcIwhfGi{ZXWgcXRQWiCxdYTweZR{Mlv5NlE5PzZzM{C=

... Click to View More Cell Line Experimental Data

In vivo Administration of PP242 is able to completely inhibit the phosphorylation of Akt at S473 and T308 in fat and liver of mice. PP242 only partially inhibits the phosphorylation of Akt in skeletal muscle and is more effective at inhibiting the phosphorylation of T308 than S473, despite able to fully inhibit the phosphorylation of 4EBP1 and S6. [2] Oral administration PP242 potently delays the leukemia onset in the mice model, and induces leukemia regression by inhibiting mTORC2 and mTORC1 activation that correlates with loss in cell size. [3] PP242 treatment potently inhibits the growth of 8226 cells in mice. [4]
Features One of the first selective inhibitors that targets ATP domain of mTOR.

Protocol(Only for Reference)

Kinase Assay: [1]

In vitro mTOR (FRAP1) kinase assay Recombinant mTOR is incubated with PP242 at 2-fold dilutions over a concentration range of 50-0.001 μM in an assay containing 50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl2, 0.01% Tween, 10 μM ATP (2.5 μCi of γ-32P-ATP), and 3 μg/mL BSA. Rat recombinant PHAS-1/4EBP1 (2 mg/mL) is used as a substrate. Reactions are terminated by spotting onto nitrocellulose, which is washed with 1 M NaCl/1% phosphoric acid (approximately 6 times, 5-10 minutes each). Sheets are dried and the transferred radioactivity quantitated by phosphorimaging. IC50 value is calculated by fitting the data to a sigmoidal dose-response curve using the Prism software package.

Cell Assay: [2]

Cell lines MEFs
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 72 hours
Method Cells are treated with increasing concentrations of PP242 for 72 hours in 96-well plates. After 72 hours of treatment, 10 μL of 440 μM resazurin sodium salt is added to each well, and after 18 hours, the florescence intensity in each well is measured using a top-reading florescent plate reader with excitation at 530 nm and emission at 590 nm.

Animal Study: [3]

Animal Models Syngeneic (Balbc/J) mice with mouse p190-transformed BM cells to initiate leukemia, and female NSG mice injected (i.v.) with SUP-B15ffLuc cells or human Ph+ leukemia
Formulation Dissolved in PEG400 (Carbowax polyethylene glycol)
Dosages ~60 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Apsel B, et al. Nat Chem Biol, 2008, 4(11), 691-699.

[2] Feldman ME, et al. PLoS Biol, 2009, 7(2), 0371-0383.

view more

Chemical Information

Download Torkinib (PP242) SDF
Molecular Weight (MW) 308.34
Formula

C16H16N6O

CAS No. 1092351-67-1
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 62 mg/mL (201.07 mM)
Ethanol 18 mg/mL (58.37 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

Recently Viewed Items

Tags: buy Torkinib (PP242) | Torkinib (PP242) supplier | purchase Torkinib (PP242) | Torkinib (PP242) cost | Torkinib (PP242) manufacturer | order Torkinib (PP242) | Torkinib (PP242) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us